delta 777

7 Dividend Stocks to Prove Buy-and-Hold Isn't Dead

it is sort of an interesting concept that current flash trading programs are essentially immaterial to long term buy and hold investing-kind of like the concept that if the bath water is running, the tub will eventually be full, regardless whether the drain is left open. This may somewhat persuade the foolish so long as the fill rate exceeds the drain rate, but falls apart totally when WS Greed applies their suction pump to the drain, as in the current economic debacle. This flash trading relentless drain of money from the overall market devastates the profitablity of long term holding of good companies with the same certainty that it devastates short term private traders.

J&J Comes Riding to Elan's Rescue

Elan has been suffering a horrible partnership in Tysabri with Biogen, who may have been sandbagging Tysabri to promote their competing drug Avonex, meanwhile salivating at the prospect of being able to make a hostile move to buy Elan's interest in Tysabri for pennies, against a very weak Elan in 2010 when standoff clauses in their partnership expire.
Wyeth/AHP is potentially also a wolf in sheeps clothing with respect to their bapineuzumab partnership with Elan (anyone remember Immunex?-R.I.P.) and when Pfizer acquires Wyeth, this cabal can not be anticipated to behave like angels in their partnership behavior
Even more significant than the much needed direct financial boost that Elan has been needing to set up, JNJ has both sufficient clout and a big enough legal department to deal with the pack of hyenas that have been circling to pick Elan's bones as well as an excellent background to insure that bapineuzumab will be properly guidedto market, even though they do not (nominally) have control of this drug. The JNJ/Elan arrangement also is a great protection of other Elan pipeline drugs against the type of manipulation that Tysabri has suffered at the hands of Biogen. JNJ has a pretty good rep as an ethical outfit.
Somewhat disturbing is key scientists Selkoe and Bloom stepping down from the Elan Board of Directors.